^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

engineered autologous T cells

i
Other names: engineered autologous T cells, autologous chimeric T lymphocytes targeted to prostate-specific membrane antigen (PSMA)
Associations
Company:
Memorial Sloan-Kettering Cancer Center
Drug class:
PSMA-targeted CAR-T immunotherapy
Associations
5ms
Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC) (clinicaltrials.gov)
P1, N=13, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
Trial completion date • Trial primary completion date • Metastases
|
cyclophosphamide • engineered autologous T cells
over1year
Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC) (clinicaltrials.gov)
P1, N=13, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Jun 2023 --> Jun 2024
Trial completion date • Trial primary completion date • Metastases
|
cyclophosphamide • engineered autologous T cells